drugset / Trial / NCT00319137

An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine

NCT00319137

Phase 2 Completed 126 enrolled GlaxoSmithKline
RandomizedSingle-groupSingle-blindTreatment

Summary

Nitric oxide (NO) is likely to be involved in the development of migraine headache. Nitric oxide synthase (NOS) is an important chemical involved in the production of NO. Reduction of NOS, and therefore NO, may be an effective technique for the treatment of migraine headache. GW274150 is a highly selective inhibitor of NOS and offers the potential of anti-inflammatory activity in migraine through a novel mechanism of action. The intent of this study is to investigate the safety and efficacy of GW274150 for the acute treatment of migraine headache.

Timeline

Start
2005-12
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject GW274150 Small molecule

Indications